Background: The employment status of workers with chronic hepatitis C has important implications for societyand labor market, for organizations and for the individuals and their economic, social and psychological status. Toevaluate the effects to Peg-IFN-α and RBV treatment on work ability (WAI) and perceived on work stress (PWS). Onehundred forty-four patients consecutive with chronic hepatitis C had been enrolled and treated withPegylated-Interferon-α 2b at dose 1.5 mg/kg per week plus daily oral Ribavirin for 12 months. The workability (WA) and perceived work stress (PWS) were evaluated. The baseline value of PWS and WAI werecompared to the values obtained at end of months 1, 3, 6, 12 and at follow up. At the end of the study wehave also compared the following groups: pretreatment, end treatment response (ETR), sustained response, noresponse, and relapse.Results: The comparison between end treatment response (ETR) and sustained viral response (SVR) showed asignificant difference in PWS. Comparison between ETR and both non responders (NR) and relapser showedsignificant differences in perceived work stress p < 0.01 and work ability index p < 0.05.Conclusions: HCV workers, treated with Peg-IFNα 2b plus Ribavirin, shows work performance loss, a decreaseof work ability at 1 month and increase in work ability in patients with end on treatment response and insustained responders decrease in perceived work stress.Trial registration: This is not a registered study as an observational study. We measured the job performancein subjects who was undergoing to the gold standard therapy for Hepatitis C at the moment of ourevaluation.

Job performance in chronic hepatitis C virus patients treated with pegylated interferon-α2b plus ribavirin: an observational study

Malaguarnera G
;
BERTINO, Gaetano
Conceptualization
;
Gagliano C;Motta M;CHISARI, Giuseppe;RAPISARDA, VENERANDO;Vecchio M;DRAGO, Filippo;Malaguarnera M.
2017-01-01

Abstract

Background: The employment status of workers with chronic hepatitis C has important implications for societyand labor market, for organizations and for the individuals and their economic, social and psychological status. Toevaluate the effects to Peg-IFN-α and RBV treatment on work ability (WAI) and perceived on work stress (PWS). Onehundred forty-four patients consecutive with chronic hepatitis C had been enrolled and treated withPegylated-Interferon-α 2b at dose 1.5 mg/kg per week plus daily oral Ribavirin for 12 months. The workability (WA) and perceived work stress (PWS) were evaluated. The baseline value of PWS and WAI werecompared to the values obtained at end of months 1, 3, 6, 12 and at follow up. At the end of the study wehave also compared the following groups: pretreatment, end treatment response (ETR), sustained response, noresponse, and relapse.Results: The comparison between end treatment response (ETR) and sustained viral response (SVR) showed asignificant difference in PWS. Comparison between ETR and both non responders (NR) and relapser showedsignificant differences in perceived work stress p < 0.01 and work ability index p < 0.05.Conclusions: HCV workers, treated with Peg-IFNα 2b plus Ribavirin, shows work performance loss, a decreaseof work ability at 1 month and increase in work ability in patients with end on treatment response and insustained responders decrease in perceived work stress.Trial registration: This is not a registered study as an observational study. We measured the job performancein subjects who was undergoing to the gold standard therapy for Hepatitis C at the moment of ourevaluation.
Interferon, Ribavirin, Hepatitis C, Fatigue, Work
File in questo prodotto:
File Dimensione Formato  
Job performance in chronic hepatitis C.pdf

accesso aperto

Tipologia: Documento in Post-print
Dimensione 850.47 kB
Formato Adobe PDF
850.47 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/51830
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact